Program
pridopidine
Also written as “Pridopidine”, “ACR16” and “pridopidine (90 mg)”.
Its studies are mostly in Huntington Disease · Amyotrophic Lateral Sclerosis · Parkinson Disease, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Prilenia | 82 open or running | phase 3since Sep 14, 2020 | Feb 28, 2011 | Mar 2028phase 3 · NCT07322003 |
| Teva Pharmaceutical Industries | 20 open or running | phase 3since Apr 22, 2008 | Apr 22, 2008 | none ahead |
Also a collaborator on its studies: Ferrer Internacional.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 22, 2008First study: phase 3 study in Huntington DiseaseNew to Teva Pharmaceutical IndustriesTeva Pharmaceutical Industries · NCT00665223 · 437 enrolled · Austria, Belgium, France and more
- Jul 24, 2008Phase 2 study in Huntington DiseaseTeva Pharmaceutical Industries · NCT00724048 · 227 enrolled · United States, Canada
- Feb 28, 2011Prilenia's first study: phase 2 study in Huntington DiseaseNew to PrileniaPrilenia · NCT01306929 · 134 enrolled
- Dec 5, 2013Phase 2 study in Huntington DiseasePrilenia · NCT02006472 · 408 enrolled · United States, Australia, Austria and more
- Jul 7, 2015Phase 2 study in Huntington DiseasePrilenia · NCT02494778 · 248 enrolled · United States, Australia, Austria and more
- Jan 3, 2017Phase 1 study in Huntington DiseasePrilenia · NCT03019289 · 23 enrolled · Germany
- Apr 17, 2019Phase 2 study in Parkinson DiseasePrilenia · NCT03922711 · 23 enrolled · United States
- Sep 14, 2020Phase 3 study in Huntington DiseasePrilenia · NCT04556656 · 499 enrolled · United States, Austria, Canada and more
- Jan 5, 2026Phase 3 study in Amyotrophic Lateral SclerosisPrilenia · NCT07322003 · 500 planned · United States, Belgium, Canada and more
- May 20, 2026Phase 3 study in Huntington DiseasePrilenia · NCT07609108 · 400 planned · United States, Belgium, Canada and more
Ahead
- Mar 2028Primary completion: phase 3 study in Amyotrophic Lateral SclerosisPrilenia · NCT07322003
- Jun 2028Primary completion: phase 3 study in Huntington DiseasePrilenia · NCT07609108
TargetBeta
“Dopamine D2 receptor modulator”ChEMBL 37, by rule
Other programs on DRD2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Aripiprazolerule | Otsuka | phase 4 | 131 |
| Risperidonerule | Johnson & Johnson | phase 4 | 111 |
| paliperidonerule | Johnson & Johnson | phase 4 | 106 |
| Olanzapinerule | Eli Lilly | phase 4 | 76 |
| brexpiprazolerule | Otsuka | phase 4 | 70 |
| rotigotinerule | UCB | phase 4 | 64 |
| lurasidonerule | Sumitomo Pharma | phase 4 | 52 |
| Pramipexolerule | Boehringer Ingelheim | phase 4 | 44 |
| iloperidonerule | Vanda Pharmaceuticals | phase 4 | 15 |
| Cabergolinerule | Changchun GeneScience Pharmaceutical | phase 4 | 8 |
| cariprazinerule | AbbVie | phase 3 | 41 |
| lumateperonerule | Johnson & Johnson | phase 3 | 25 |
Studies
All 10 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07609108Huntington Disease · United States, Belgium, Canada and more | 3 | Recruiting | Prilenia | Jun 2028 | 400 |
| NCT07322003Amyotrophic Lateral Sclerosis · United States, Belgium, Canada and more | 3 | Recruiting | Prilenia | Mar 2028 | 500 |
| NCT04556656Huntington Disease · United States, Austria, Canada and more | 3 | Completed | Prilenia | Mar 14, 2023 | 499 |
| NCT03922711Parkinson Disease · United States | 2 | Terminated | Prilenia | Jul 22, 2020 | 23 |
| NCT03019289Huntington Disease · Germany | 1 | Completed | Prilenia | Feb 9, 2018 | 23 |
| NCT02494778Huntington Disease · United States, Australia, Austria and more | 2 | Terminated | Prilenia | Jan 12, 2018 | 248 |
| NCT02006472Huntington Disease · United States, Australia, Austria and more | 2 | Completed | Prilenia | Dec 16, 2015 | 408 |
| NCT01306929Huntington Disease | 2 | Completed | Prilenia | Jan 5, 2018 | 134 |
| NCT00724048Huntington Disease · United States, Canada | 2 | Completed | Teva Pharmaceutical Industries | Jul 26, 2010 | 227 |
| NCT00665223Huntington Disease · Austria, Belgium, France and more | 3 | Completed | Teva Pharmaceutical Industries | Jun 14, 2010 | 437 |
How it is read
Names in the registry
- “Pridopidine”, 6 entries
- “ACR16”, 2 entries
- “pridopidine”, 1 entry
- “pridopidine (90 mg)”, 1 entry
Conditions, from the studies’ own filings
- Huntington Disease, 8 studies
- Amyotrophic Lateral Sclerosis, 1 study
- Parkinson Disease, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.